The Role of Anatomic and Functional Imaging in Myeloma
multiple myeloma is a heterogeneous disease which can present with or without overt symptomatology.1 The heterogeneity relates both to the intrinsic biology of the myeloma cells and bone marrow microenvironment and to systemic host responses to the myeloma.2 The patient's age, health status, and the time of presentation to the healthcare system all impact outcome.
In an effort to standardize the treatment approaches, it is essential to characterize the disease as clearly as possible at the time of diagnosis. The Durie/Salmon myeloma staging system was introduced in 1975 to permit easy clinical staging, which correlated with measured myeloma cell mass.3 This system has been widely used over the past 30 years. Despite the fact that classification based on the number and extent of bone lesions found on X-ray is observer dependent, the system has proved to be remarkably reliable.4,5Nonetheless, the availability of much more sensitive imaging techniques has mandated the...
KeywordsMyeloma Cell Indolent Disease Extramedullary Disease MIBI Imaging Soluble Receptor Activator
- 4.Gahrton G, Durie BGM, et al. Multiple Myeloma and Related Disorders, The role of imaging in myeloma. Arnold 2004; 10: 155–63.Google Scholar
- 11.Walker R, Jones-Jackson L, et al. Diagnostic imaging of multiple myeloma-–FDG PET and MRI complementary for tracking short vs long term tumor response [abstract #758]. Blood. 2004; 104(11): 217a.Google Scholar
- 14.Walker R, Barlogie B, et al. Prospective evaluation of 460 patients from total therapy II - —identification of characteristics on baseline MRI examinations of prognostic significance - —importance of focal lesions (FL) in multiple myeloma (MM). Hematol J. 2003; 4: S171. Abstract 188.CrossRefGoogle Scholar
- 16.Walker RC, Barlogie B, Shaughnessy J. DKK1 in myeloma: correlation with FDG-PET. New Engl J Med. 2004; 350(14): 1465–6.Google Scholar
- 19.Fonti R, Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant pheno-type by 99mTcMIBI scan in patients with multiple myeloma. 2004; 19(2): 165–70.Google Scholar
- 20.Durie BGM, et al. Technetium-99m-MIBI scanning in multiple myeloma (MM): comparison with PET (FDG) imaging. Blood 1996; 88: 10. Abstract 1559.Google Scholar
- 22.Durie BGM, Waxman AD, D'Agnolo A. A whole-body Tc-99m-MIBI scanning in the evaluation of multiple myeloma (MM). J Nucl Med. 1998; 39: 138.Google Scholar
- 29.Walker R, Barlogie B, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic diagnostic and clinical implications. J Clinic Oncol. 25(9):1121–28.Google Scholar
- 31.Moran GR, Pekar J, Bartolini M, et al. An Investigation of the toxicity of gadolinium based MRI contrast agents. Proc Intl Soc Mag Reson Med. 2002. 10.Google Scholar
- 33.Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry. J Clin Onco. 2008; 26(13). (Published ahead of print.)CrossRefGoogle Scholar